Skip to content

13F-HR filed by Sarissa Capital Management LP

Sarissa Capital Management LP filed this 13F-HR for the quarter ended 2024-03-31, filed 2024-05-15, with 10 holding rows worth $571,629,246.

Accession
0000899140-24-000608
Filed
2024-05-15
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2024

A holdings report, 10 entries on the cover page, a total value of $571,629,246 stated on the cover page (in dollars after the unit check, H1), rows summing to $571,629,246 with VALUE read as dollars as filed, 13F file number 028-15935. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
IRONWOOD PHARMACEUTICALS INC46333X108COMMON STOCK16,390,000$142,756,900dollars as filed
BIOGEN INC COM09062X103Stock643,000$138,650,090dollars as filed
INNOVIVA INC45781M101COM7,277,000$110,901,480dollars as filed
Gilead Sciences,Inc.375558103COM1,103,282$80,815,407dollars as filed
NEUROCRINE BIOSCIENCES INC64125C109COM346,426$47,779,074dollars as filed
AMARIN CORP PLC023111206SPONS ADR NEW24,850,623$22,136,935dollars as filed
CYTOKINETICS INC23282W605COM NEW300,000$21,033,000dollars as filed
BIOCRYST PHARMACEUTICALS INC COM09058V103Stock1,094,168$5,558,373dollars as filed
VOR BIOPHARMA INC929033108COM618,000$1,464,660dollars as filed
REGULUS THERAPEUTICS INC75915K309COM185,183$533,327dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000899140-24-000608this filing2024-05-15acceptance time not in the bulk data set